Work

Supplementary Figure S5 from Combined MEK and BCL-2/XL Inhibition Is Effective in High-Grade Serous Ovarian Cancer Patient–Derived Xenograft Models and BIM Levels Are Predictive of Responsiveness

Year: 2023

Type: supplementary-materials

Abstract: Supplementary Figure S5 describes the Correlation of positive predictors before and after MEK inhibition; validation of BIM as a predictor of drug response in an independent set of ovarian cancer cell lines; predictive model including baseline levels of BIM and pERK

DOI: 10.1158/1535-7163.22505622

Authors: Claudia Iavarone, Ioannis K. Zervantonakis, Laura M. Selfors, Sangeetha Palakurthi, Joyce F. Liu, Ronny Drapkin, Ursula A. Matulonis, Dorothy Hallberg, Victor E. Velculescu, Joel D. Leverson, Deepak Sampath, Gordon B. Mills, Joan S. Brugge

Language: English

Topic: Ovarian cancer diagnosis and treatment

Subfield: Reproductive Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

OpenAlex ID: W4362609969

Cites:

Cited by:

Related to: 10